PDF) A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease
Madopar (co-beneldopa): for treatment of Parkinson's disease symptoms
MADOPAR HBS caps. 100/25 100 caps
Pharmaceutics | Free Full-Text | 3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects - ScienceDirect
PDF) Levodopa delivery from controlled-release polymer matrix: Delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats
Levodopa Benserazide 250 at Rs 125/piece | Pharmaceutical Tablets in Nagpur | ID: 26499598191
A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. - Abstract - Europe PMC